Last reviewed · How we verify
Utidelone plus Intermittent Capecitabine
Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers.
Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers. Used for Acute myeloid leukemia (AML), Diffuse large B-cell lymphoma (DLBCL).
At a glance
| Generic name | Utidelone plus Intermittent Capecitabine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Plk1 inhibitor |
| Target | Plk1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting Plk1, Utidelone disrupts the cell cycle, leading to cell death in cancer cells. This mechanism is particularly effective in cancers with high Plk1 expression, such as certain types of leukemia and lymphoma. The addition of intermittent Capecitabine, a chemotherapy agent, further enhances the anti-tumor effects of Utidelone.
Approved indications
- Acute myeloid leukemia (AML)
- Diffuse large B-cell lymphoma (DLBCL)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: